Beleodaq (belinostat)

News alerts, weekly reports and conference planners

Company:

Assertio, Aurobindo, Valerio Therap

Drug class:

HDAC inhibitor

Related drugs:

‹

›

No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	belinostat Sensitive: A1 - Approval belinostat Sensitive : A1	belinostat Sensitive: A1 - Approval belinostat Sensitive : A1
BRAF mutation + TET2 mutation	Acute Myelogenous Leukemia	BRAF mutation + TET2 mutation	Acute Myelogenous Leukemia	MLN4924 + belinostat Sensitive: C4 – Case Studies MLN4924 + belinostat Sensitive : C4	MLN4924 + belinostat Sensitive: C4 – Case Studies MLN4924 + belinostat Sensitive : C4

Associations
(2)